

Company Overview

Craig Cooper - Chief Executive Officer Niall Cairns - Executive Chairman

August 2020





OUR MISSION To reduce the global impact of cardiovascular disease. CardieX technology in over a billion homes and clinics worldwide.





KEY COMPANY HIGHLIGHTS

Core technology measures risk & vital signs for arterial & vascular disease.

A world-leader in measuring arterial stiffness and central blood pressure.

World Leading "cuffless" medical sensor technology.

Only FDA-cleared non-invasive measurement of arterial health.

On track for the release of multiple new devices (FDA 'fast track' clearance to be obtained) in 2021 targeting key new markets.

Significant ecosystem of new partnerships and licensing revenue.


Substantial patent, trademark, and IP portfolio.





WE'RE SOLVING A GLOBAL PROBLEM

Cardiovascular (CV) disease is the CARDING CONTRACTOR OF MUMANS Globally 1





Incidence rate continues to rise

Current blood pressure (BP) monitoring solutions do not accurately identify or prevent CV risk





Traditional blood pressure monitors do not measure a specific **individual's risk** for hypertension, cardiovascular disease, and other health disorders.

Global regulatory and policy support calls for more accurate diagnosis of heart diseases based on arterial stiffness.

THE LANCET



World Health Organization



OUR MARKET

We're focused on the largest health technology markets - cardiovascular & arterial disease and wearable remote patient monitoring.





Current products cover only a small percentage of our total addressable market - specialist clinicians (cardiologists, nephrologists), researchers, and clinical trial services.





1.3B

Global Hypertensives ⁶

(USA 46% of adult population).

1M+ USA based physicians and clinicians.

Future product portfolio expands our

technology into the consumer/home, digital, wearable, hospital, and general clinician markets through a mix of company owned products/licensing/OEM partnerships - all "Powered by ATCOR".



POWERED BY ATCOR






RELEVANCE DURING PANDEMICS

*


Leading Comorbidities among COVID-19 Deaths in New York ⁷

	• Hypertensi	
	Diabet	
	Hyperlipiden	
	 Coronary Artery Disea 	
	Renal Disea	
	• Demen	
	CO	
Our SphygmoCor® technology is Can a market leader in the non-invasive Atrial Fibrillation Atrial Fibrillation		

 Our new product development is focused on home and wearable solutions for identifying arterial inflammation and overall risk for other arterial health disorders.



Exclusively selected by the Artery Society to measure CBP and arterial stiffness in the CARTESIAN Study - largest study to date on COVID and hypertension.



The Hospitalist



OUR CURRENT SOLUTIONS

CardieX's ATCOR division develops and licenses products that precisely measure individual risk for hypertension & vascular disease.

- Patented technology measures "<u>central</u> blood pressure" at the aorta/heart rather than "peripheral blood pressure" at the arm as well as arterial stiffness.
- Measuring "central pressure" provides medical and consumer health parameters not otherwise attainable using traditional blood pressure devices.
- Allows more precise and accurate determination of hypertension and risk of vascular related disease such as Alzheimer's, stroke, and other inflammatory disorders.
- Two current products: XCEL and Oscar 2 ABPM
- The only technology FDA approved to measure central pressure non-invasively in adults that qualifies for Medicare reimbursement.
- Currently undertaking significant product and market expansion combined with new sales, pricing, and marketing strategies.



All "Top 20 Hospitals" use SphygmoCor technology to measure central blood pressure (cBP)



1,400+ papers have been published in leading peerreviewed journals like Hypertension, Journal of *Clinical Hypertension*, and the Journal of the American College of Cardiology



8 out of Top 10 Pharma companies have used SphygmoCor technology in their clinical trials

Over **11,000 patients** have been tested with SphygmoCor technology in pharmaceutical trials







CENTRAL BLOOD PRESSURE CardieX's Complete Vital Signs Solution

Central Blood (cBP) + arterial stiffness provides **complete BP measurements**.

Gold-standard non-invasive cBP in addition to standard BP numbers.



Numerous **medical grade measurements** for heart & arterial health.

OUR PARTNERS & CUSTOMERS We Currently Sell/Lease XCEL SphygmoCor[®] and Related Products to:

Research and Pharmaceutical companies for clinical trial services related to CVD and hypertension.

Specialist practices-principally Cardiologists, **Nephrologists and Endocrinologists** for measurement of **pulse wave** and cBP (central blood pressure).

IDN/health care service providers in the USA for sale to their affiliate hospital and caregiver networks.


Licensing agreement with SunTech Medical for 24-hour Ambulatory Blood Pressure Measurement (ABPM) for Oscar 2 SphygmoCor[®] device.













THE FUTURE An ecosystem of connected devices & apps designed to improve daily wellbeing and long-term health.



NEW PRODUCT DEVELOPMENT OVERVIEW

- Mutliple new products and revenue streams on tr
- A complete device & software solutions infrastrue
- Comprehensive vital signs monitoring solutions.



	DPMEN	TOVE	ERVIEV	V	
track for 2020/2021.		Devices Partnerships Digital	Now 2 1 0	2021 5 3 3	
d) 5)	<section-header><section-header><section-header><section-header><list-item><list-item><list-item><list-item></list-item></list-item></list-item></list-item></section-header></section-header></section-header></section-header>		<section-header><section-header><section-header><list-item><list-item><list-item><list-item><list-item></list-item></list-item></list-item></list-item></list-item></section-header></section-header></section-header>		
	Market Opport \$USD 37 Source: Industry Stats R	B ³	Market Opport \$USD 500 Source: Grand View Rese	98 ⁵	11

- Customizable modules and over-the-air feature upgrades.
- "beyond blood pressure".
- Over 15 programmable health data features at launch (Arty™).
- health management.



WEARABLE SENSOR & TECHNOLOGY LICENSING

95.

Licensed and Company Owned Wearables Based on our Arty™ Platform.

Breakthrough technology for monitoring heart and arterial health with wearable devices.

No commercially available wearable can produce all our heart & arterial health features.

Built on the foundation of our **patented** SphygmoCor[®] technology.

Significant applications across medical and consumer patient populations and general health monitoring.

First phase studies successfully completed. Currently being implemented into partner (Mobvoi) & new CardieX devices.





WEARABLE SENSOR & TECHNOLOGY LICENSING CONT.

Finger-Based PPG Sensor




Processing & Transforming

٩

- Unique heart & arterial indicators
- Calculated from heart pressure pulse from a finger-based PPG sensor



U.S. Patent Pending 63/031645





IOMT - "INTERNET OF MEDICAL THINGS"

An ecosystem of connected medical devices and solutions remotely connecting patients, consumers, and physicians all powered by our SphygmoCor® technology & Arty™ cloud infrastructure.





CARDIEX GOALS IN 2020 & 2021

Significant expansion of new product lines.

Launch of 8 new devices and associated software/ digital solutions.

Multiple growth and revenue inflection points throughout the year.

Targeting 3 new FDAclearances in 2021 in consumer, medical, and wearables.



 \sim


World-leading new health data features derived from our SphygmoCor[®] technology.



Multiple new partnerships and licensing of our cBP and wearable sensor technology.



Launch of Mobvoi smartwatch. Commercialization of Blumio sensor partnership.






Cardie



Launch of Arty™ app, cloud, SaaS, and clinician software infrastructure.



FINANCIALS



SALES GROWTH DRIVEN BY Product and Tech Transformation

Existing Business Revenue

Technology Licensing

Professional (ATCOR)

(FY 2020 Unaudited Revenue)



FY24 Revenue Streams

Technology Licensing

Digital & SaaS (including Wearables)

Professional (ATCOR)

Home/Clinician Device

(Target Revenue Mix)



PRODUCT REVENUE METRICS (est)

SALES TARGET

Professional (XCEL)

Digital (App + SaaS)

Clinician

Home &

Wearables

Research, Pharma, Specialist Clinicians

Physician (ArtyNet portal)

Consumer (Arty Go app)

Physician

Consumer (Pulse BPM)

Licensing

Patient (prescribed by Physician)

Licensing

SUCCESS DRIVER

Growing clinical recognition of cBP.

CPT remimbursement.

Bundled sale with new devices.

CPT reimbursement and advanced diagnostics.

Direct marketing & physician referrals.

Direct sales and marketing to OEM's + device makers.

Remote patient monitoring reimbursement (ABPM).

World-first medical and consumer health data features.

\$ PER SALES EVENT	GROSS MARGIN	TOTAL ADDRESSABLE MARKET
\$7,500	>80%	\$USD5B
\$200 p/month.	N/A	~\$7.5B for US in 2020, \$17B in US by 2026
\$9.99 p/month	N/A	~\$15B WW in 2020, \$111B WW by 2025
\$1,000	>70%	1M USA based MD's and clinicians.
\$99	>60%	\$USD3B (2025)
Licensing revenue, chip sales + revenue share.	>80%	\$USD3B (2025)
Chip sales + revenue share.	>80%	\$USD3B
Royalty fee based on per unit sale	>80%	\$USD37B (2025)



APPENDICES

Board of Directors Key Management Locations & Teams Corporate History CardieX Cloud Infrastructure References





BOARD OF DIRECTORS



Executive Director & CEO Craig R. Cooper

BEc, LLB (Hons)

Co-Founder – NRG Asia–Pacific Senior Associate Lawyer - Blake Dawson Waldron - counsel to United Airlines, The Disney Corporation, DHL International **Co-Founder** – Boost Mobile USA **TV Host & Investor** - CNBC's "Adventure Capitalists" Head of Venture Capital and Digital Media – Saban Capital (USD\$700M) **Founding Partner** - Softbank Capital (USD\$500M) **Venture Partner** - VantagePoint Capital Partners (USD\$3B)



Executive Chairman Niall Cairns

BEC, ACA, FAICD

Managing Partner - Kestrel Capital Pty Limited **Chairman** - Tambla Limited (ASX:TBL) **Director** - Chant West Holdings Limited (ASX:CWL) **Director** - Carbine Agri-Investment Limited (formerly Tru-Test Corporation Limited) Managing Partner - Kestrel Growth Funds Managing Partner - Carnethy Evergreen Fund



Non-Executive Director R. King Nelson

BA, MBA


Director - Regenesis Biomedical President, CEO & Director - Uptake Medical **Director** - Digirad (NASDAQ:DRAD) **President, CEO & Director** - Kerberos Proximal Solutions **President, CEO & Director** - VenPro Medical (Medtronic) **Division President** - Baxter Healthcare (various businesses) Sales & Marketing - American Hospital Supply



Executive Director, Chief Financial Officer Jarrod White

BCom., CTA

Traverse Accountants University of Sydney





KEY MANAGEMENT



Chris Dax **President of ATCOR**

Masimo ISTA Pharmaceuticals Elan Pharmaceuticals Valeant





ZiHan Lin

VP of Corporate Development

Masimo Uptake Medical Harvard / Stanford



Cochlear Silverbrook Research




Ahmad Qasem

Director of Research & Applications

PhD in Biomedical Engineering Macquarie University



Doug Kurschinski **EVP & Head of Global Sales**





Rhonda Welch **VP of Health Economics**

J&J - Biosense Webster Baxter Healthcare

Lawrence Chan

Director of Product Development



Dan Posnack

Director of Product Development – Digital Health

ROM Technologies Modernizing Medicine **DNA Interactive**

Sameer Molvi

Sr. Engineering Program Mgr.

Commissioning Agents Breathe Technologies UC Irvine

Antony Sloan

Global Head of Marketing & Communications

Masimo Steris Avery Dennison





LOCATIONS & TEAMS

blümio

SYDNEY **ATCOR Corporate ATCOR**



SILICON VALLEY Partnership with Blumio

LOS ANGELES inHealth Corporate



ORANGE COUNTY CardieX Executive & Corporate


Cardie

CHICAGO **ATCOR Sales Management ATCOR**






CORPORATE HISTORY




CARDIEX CLOUD INFRASTRUCTURE





REFERENCES

- 1. World Health Organization. <u>https://www.who.int/health-topics/cardiovascular-diseases/#tab=tab_1</u>
- 2. Fortune Business Insights. <u>https://www.fortunebusinessinsights.com/industry-reports/blood-pressure-monitors-</u> market-100059
- 3. Industry Status Report. https://industrystatsreport.com/Lifesciences-and-Healthcare/Medical-Wearables-Market-Size-and-Growth/Summary
- 4. Valuates Reports. <u>https://reports.valuates.com/market-reports/QYRE-Othe-OA163/digital-health-market</u>
- 5. Grand View Research. <u>https://www.grandviewresearch.com/press-release/global-digital-health-market</u>
- 6. Journal of American Society of Hypertension. <u>https://www.sciencedirect.com/science/article/abs/pii/S1933171116304892?</u> <u>via%3Dihub</u>
- 7. **The Hospitalist.** <u>https://www.the-hospitalist.org/hospitalist/article/220457/coronavirus-updates/comorbidities-rule-new-yorks-covid-19-deaths</u>





CONTACT

Craig Cooper CEO <u>ccooper@cardiex.com</u>

Niall Cairns Executive Chairman nccairns@cardiex.com



